SCHEMBL16029633

SCHEMBL16029633

Fc1c(Br)ccc2nonc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
GAA P10253 2/20 0.38
KMT2A Q03164 5/20 0.36
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 4/20 0.36
USP2 O75604 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
HSD17B10 Q99714 2/20 0.35
LMNA P02545 1/20 0.34
KDM4E B2RXH2 3/20 0.34
TSHR P16473 2/20 0.34
NPC1 O15118 1/20 0.34
EPAS1 Q99814 4/20 0.34
ARNT P27540 3/20 0.34
ENPP2 Q13822 1/20 0.33
L3MBTL1 Q9Y468 4/20 0.33
POLB P06746 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15573003 0.80 MAPT (0.41) MAPTGAAKMT2AALDH1A1MEN1
SCHEMBL16029651 0.75 MAPT (0.45) MAPTGAAKMT2AALDH1A1MEN1
SCHEMBL16029956 0.75 MAPT (0.38) MAPTGAAKMT2AALDH1A1MEN1
SCHEMBL680567 0.71 MAPT (0.38) MAPTGAAKMT2AMEN1HSD17B10
SCHEMBL1420436 0.70 KMT2A (0.46) MAPTGAAKMT2AALDH1A1MEN1
SCHEMBL25222485 0.68 ADRA2A (0.41) MAPTKMT2AALDH1A1MEN1USP2
SCHEMBL30486566 0.68 ADRA2A (0.41) MAPTKMT2AALDH1A1MEN1USP2
SCHEMBL16029565 0.67 MAPT (0.41) MAPTGAAKMT2AALDH1A1MEN1
SCHEMBL6390857 0.65 KMT2A (0.46) MAPTGAAKMT2AALDH1A1MEN1
SCHEMBL29666934 0.65 KDM1A (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 WO disclosed
EP-2970186-B1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2020-06-10 EP disclosed
EP-2970186-B1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2020-06-10 EP disclosed
US-9006250-B2 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides DOW AGROSCIENCES LLC (US) 2015-04-14 US disclosed
US-9006250-B2 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides DOW AGROSCIENCES LLC (US) 2015-04-14 US disclosed
US-9006250-B2 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides DOW AGROSCIENCES LLC (US) 2015-04-14 US disclosed
WO-2014151009-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC) PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2014-09-25 WO disclosed
US-20140274702-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES, LLC (US) 2014-09-18 US disclosed
US-20140274702-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES, LLC (US) 2014-09-18 US disclosed
US-20140274702-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES, LLC (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 MAPT 4580/4885GAA 4385/4885KMT2A 3316/4885
US-20140274702-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DDT, ABAT, PAH MAPT 1821/4885GAA 2789/4885KMT2A 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.